• Canada’s Drug Agency issued a final positive recommendation to reimburse BioArctic-partnered Leqembi for eligible early Alzheimer’s patients.
• Decision followed a reconsideration, boosting prospects for public coverage across Canada’s provinces and territories.
• Next step shifts to pan-Canadian Pharmaceutical Alliance price talks, a key gate to provincial reimbursement decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 202609010100BITN____UKPR__EN_20260831-BIT-4531-0) on September 01, 2026, and is solely responsible for the information contained therein.